These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12233877)

  • 1. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes.
    Glossop JR; Dawes PT; Hassell AB; Mattey DL
    J Rheumatol; 2005 Sep; 32(9):1673-8. PubMed ID: 16142859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
    de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A
    J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis.
    Fabris M; Di Poi E; D'Elia A; Damante G; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Jan; 29(1):29-33. PubMed ID: 11824966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
    Glossop JR; Dawes PT; Nixon NB; Mattey DL
    Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis.
    Glossop JR; Nixon NB; Dawes PT; Hassell AB; Mattey DL
    J Rheumatol; 2003 Jul; 30(7):1406-9. PubMed ID: 12858434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity.
    Dieudé P; Petit E; Cailleau-Moindrault S; Osorio J; Pierlot C; Martinez M; Fauré S; Alibert O; Lasbleiz S; De Toma C; Bardin T; Prum B; Cornélis F;
    Arthritis Rheum; 2002 Aug; 46(8):2039-44. PubMed ID: 12209506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.
    Rizzo R; Rubini M; Govoni M; Padovan M; Melchiorri L; Stignani M; Carturan S; Ferretti S; Trotta F; Baricordi OR
    Pharmacogenet Genomics; 2006 Sep; 16(9):615-23. PubMed ID: 16906016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.
    Schotte H; Schlüter B; Drynda S; Willeke P; Tidow N; Assmann G; Domschke W; Kekow J; Gaubitz M
    Ann Rheum Dis; 2005 Apr; 64(4):575-81. PubMed ID: 15345504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No association between tumour necrosis factor receptor type 2 gene polymorphism and rheumatoid arthritis severity: a comparison of the extremes of phenotypes.
    van der Helm-van Mil AH; Dieudé P; Schonkeren JJ; Cornélis F; Huizinga TW
    Rheumatology (Oxford); 2004 Oct; 43(10):1232-4. PubMed ID: 15252214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor alpha 5'-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis.
    Shibue T; Tsuchiya N; Komata T; Matsushita M; Shiota M; Ohashi J; Wakui M; Matsuta K; Tokunaga K
    Arthritis Rheum; 2000 Apr; 43(4):753-7. PubMed ID: 10765919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.